No Data
No Data
Guoyuan Securities 2025 CSI SWS Health Care index investment strategy report: Bullish on innovation and overseas expansion, focusing on upward fundamental segmentation tracks.
The international expansion of the pharmaceutical industry remains an essential path for our country's pharmaceutical companies in the future, and companies with strong product capabilities and channel capabilities are expected to gain an advantage.
An alternative "going abroad" for centralized procurement of pharmaceuticals and medical devices? The China-ASEAN regional centralized procurement platform for pharmaceuticals has been launched, and the industry anticipates the birth of the first Order.
① Today, the China-ASEAN pharmaceutical regional procurement platform officially launched, with representatives from Shenzhen Mindray Bio-Medical Electronics, United Imaging Healthcare, SIMCERE PHARMA, and other companies present; ② Although the specific implementation plan is yet to be clarified, the industry believes it is undoubtedly Bullish for domestic pharmaceutical companies; ③ The Southeast Asian pharmaceutical market is growing rapidly, but it relies heavily on imported drugs and medical devices.
Gelonghui Announcement Selection (Hong Kong Stocks) | CGN POWER (01816.HK) plans to acquire 100% equity of Taishan Second Nuclear Power for 1.2 billion yuan.
【Today's Focus】CGN POWER (01816.HK) plans to acquire 100% equity of Taishan Nuclear Power for 1.2 billion yuan. CGN POWER (01816.HK) announced that on January 8, 2025, the Board of Directors reviewed and approved the resolution for the company (as the acquirer) to enter into an Equity Transfer agreement with CGN (as the transferor). According to the Equity Transfer agreement, CGN agrees to sell, and the company agrees to acquire, 100% equity of Taishan Nuclear Power, with a total consideration of 1,203.8756 million yuan. Taishan Nuclear Power was established on January 13, 2011, as of the date of the Equity Transfer agreement by CGN.
CMS (00867.HK) signed a licensing, collaboration, and distribution agreement for the modified new drug ZUNVEYL, aimed at treating mild to moderate Alzheimer’s dementia symptoms.
On January 8th, Gelonghui reported that CMS (00867.HK) announced that on January 8, 2025, the group signed a licensing, collaboration, and distribution agreement with Alpha Cognition Inc. ("Alpha") through its wholly-owned subsidiary for the improved new drug ZUNVEYL (benzgalantamine delayed-release tablets) ("ZUNVEYL" or "product") for the treatment of mild to moderate Alzheimer's disease symptoms. According to the agreement, the group obtained the rights in Asia (excluding Japan),
Express News | China Medical System - Under Deal, Group to Have Exclusive Right to Develop, Others, Product in Asia (Excluding Japan), Australia and New Zealand
Express News | China Medical System - Agreement for Improved New Drug Zunveyl for Treatment of Mild-to-Moderate Dementia of Alzheimer's Type